The Trump administration is “very eager” to create a pathway for access to psychedelic therapy, Robert F. Kennedy Jr. According to the secretary of the US Department of Health and Human Services (HHS), and senior officials of federal agencies want to “communicate to the public as soon as possible.”
In an interview on the Joe Rogan Experience podcast released Friday, Kennedy said he’s confident “we’re going to get it,” with plans to develop and finalize rules that would allow patients with conditions like post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled environment.”
The secretary has been noted for his advocacy of psychedelic reform, an idea he floated as a 2024 Democratic presidential candidate before ultimately becoming the nation’s top health official under the Trump administration.
The president himself has been silent on the issue, but as Kennedy points out, support for expanding access to research and new therapeutics extends beyond HHS, with the heads of the US Department of Veterans Affairs (VA), the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) also looking to take advantage of the potential benefits of psychedelic drugs.
“Everybody in my agency, and in (Secretary Doug Collins’) agency at the VA, is very eager to get a rule that will allow these types of studies and allow them to go into therapeutic settings, particularly for military personnel who have suffered these injuries to have access to these products,” Kennedy said. “We are working on that process now. We are all working and trying to make it happen.”
“I think we’ll make it.”
While some of the reform proposals being considered would be designed to “encourage more clinical trials” while having “very strong guidelines,” the health secretary said the agencies are interested in the full range of options that could include psychedelic therapies and other “rapid interventions.” One of Kennedy’s personal goals would be to validate the utility of substances like psilocybin over SSRIs for depression.
“We’re looking at that as a whole category of interventions that people should be able to look at and have appropriate access to, and we should roll it out as quickly as possible,” he said.
“This is what we’re anticipating, so I can’t tell you exactly what we’re going to do, but very, very strong therapeutic guidelines, so how they’re applied, what kind of follow-up. Because a lot of these things rewire the brain. If you don’t follow-up, it doesn’t work, or you have a failure rate. So we’re developing all of those things and I think we’re developing protocols. People in the administration are eager to do that as soon as possible. I know Doug Collins is doing 21 studies at the VA that they are doing, that they are very promising.
“You need those guidelines because you don’t want to do the Wild West. You can have horror stories overnight because some people can have very, very bad experiences,” Kennedy said. “We’re looking at ways to do it so it’s in a very controlled environment.”
Asked to expand on how Rogan sees the future of psychedelic therapies and whether it will include people in the military or other non-frontline roles, the secretary said he would “personally” like to see broad access, but “we have to take baby steps because you don’t want to create a situation where people want to get hurt.”
However, “you shouldn’t have a soldier who has given everything for the country, who has suffered terribly, who has come to Tijuana to receive these treatments, leave our country to receive treatments,” he said. “It doesn’t make sense.”
“I’ve seen so much overwhelming anecdotal evidence,” Kennedy said, emphasizing that one of his relatives has benefited from psychedelic therapy“but also clinical studies that verify the effect.” And officials at agencies like the NIH and FDA are “doing everything they can to make that happen.”
Last October, Kennedy specifically criticized the FDA under the previous administration for the agency’s “eradication of psychedelics” and a laundry list of other issues that he said was a “war on public health” that would end under the Trump administration.
Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.
Dalgety Ltd has entered into a partnership with Curaleaf Laboratories to supply pharmaceutical grade cannabis medicines to the UK cannabis market. The arrangement combines Dalgety’s cultivation operations, which are certified to EU-GMP standards, with Curaleaf Laboratories’ pharmaceutical manufacturing and distribution capabilities. According to the companies, this creates a UK-based supply route that does not rely on imported cannabis flowers, as Dalgety cultivates its product in-house. Dalgety claims it was the first company in the UK to grow, manufacture and supply EU-GMP medical cannabis from a single site.
The growing facility, which is more than 30,000 square feet, is located indoors and uses hydroponic growing methods along with automated lighting, irrigation, humidity and temperature control systems. The company reports that it uses AI-assisted environmental monitoring, which extends the traceability of batches to the final product and compares them to operating standards for air filtration systems. Post-harvest processing is said to follow EU-GMP protocols, including microbial and cannabinoid testing.
The stated goal of this approach is to reduce between-harvest variation in terms of THC and CBD content, terpene profiles, and microbial safety. Dalgety says his cultivation is overseen by staff with experience in horticulture and biochemistry, some of whom have worked on cannabis cultivation projects internationally.
Through a partnership with Curaleaf Laboratories, Dalgety’s UK-grown cannabis is processed and distributed through a UK-based supply chain, rather than imported from overseas. Companies suggest that this arrangement can shorten the time it takes to get products to market compared to importing, and reduce the likelihood of supply disruptions. Because Dalgety and Curaleaf Laboratories are involved in cultivation, manufacturing and distribution, the companies say this oversees the product at every stage, making it clearer for prescribers to see where and how the product was made.
Dalgety operates to EU-GMP standards and has been subject to regulatory review by the MHRA and the Home Office. Its operations include environmental monitoring, microbial testing, stability testing, controlled drying and curing procedures and quality assurance processes, along with controlled and secure facilities.
The company describes its work as controlled environment farming, hydroponic systems, environmental control technology, and efforts to stabilize cannabis genetics and phenotypes for batch-to-batch consistency.
Dalgety has also opened its cultivation facilities for visits to healthcare professionals, clinicians, pharmacists, researchers and other industry stakeholders. The company says this is in response to the fact that much of the cannabis historically supplied to UK patients has been grown overseas, which has limited opportunities for UK clinicians to see first-hand the cultivation and quality control processes. These tours aim to provide visitors with information on cultivation standards, EU-GMP compliance procedures, environmental control systems, testing processes and the regulatory framework governing cannabis manufacturing in the UK.
Dalgety and Curaleaf Laboratories describe their partnership as expanding access to UK-grown medical cannabis, improving supply chain reliability and helping to meet sector regulations, placing it in the wider context of growing demand for cannabis-based treatments from UK patients.
After the state opened its first dispensary in 2019, thousands of Arkansans joined the program and spent a record $291.1 million on medical marijuana in 2025, according to the state Department of Finance and Administration.
Tax revenue from those sales now supports free breakfast for public school students after lawmakers passed legislation last year.
Medical marijuana programs have expanded across the country, as has recreational marijuana. Two dozen states, including neighboring Missouri, allow recreational marijuana use, according to state legislatures.
Restrictions on marijuana have been relaxed at the federal level, and the US Department of Justice earlier this year downgraded the drug classification of medicinal cannabis.
Here’s what Arkansas’ gubernatorial candidates — Democratic State Sen. Fred Love, Republican Gov. Sarah Huckabee Sanders and Libertarian Colt Shelby — have to say about legalizing recreational marijuana.
Democratic State Sen. Fred Love
Love said he opposes legalization during a debate at the Arkansas Press Association’s annual conference in June.
Sitting in a crosswalk at her daughter’s school, Love said “marijuana is all over” as the children exited their vehicles. When you grow up in a community where recreational marijuana is present, you see that it doesn’t always have a positive effect, he said.
“I don’t think it’s something I support,” Love said. “I’ve seen the long-term impact.”
While he doesn’t personally support it, Love said he would support legalizing recreational marijuana if Arkansans voted on it.
Libertarian Colt Shelby
Shelby said he’s for whatever Arkansans want, so he would support legalizing recreational marijuana if voters approve.
Shelby said the state’s elected officials have forgotten what matters most is what Arkansans want, which is why she’s running for office.
Although Shelby says she doesn’t smoke weed herself, she says almost everyone knows it and she has the meds.
“It brings a lot of good things, so I won’t say that I’m against it, but let the people decide”, he said in the debate in June.
Republican Governor Sarah Huckabee Sanders
Sanders did not participate in the June debate, but said in an emailed statement that he does not support the legalization of recreational marijuana.
“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans,” Sanders said.
Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.
The World Cup is coming to an end, with the third-place play-off between France and England on Saturday, and the final between Spain and Argentina the following day. It won’t be long until the grand winner of FreshPublishers’ first World Cup pool is revealed.
As previously reported, Slim Kooli from Courchesne Laros is the favorite to win the €1,000 prize. He has secured a comfortable lead over Nol Batist of North American Interstate Greenhouse Company, while buyer Bjorn Van Ryckeghem of Deprez Construct is currently in third place.
1
Sim School
Spain
1–0
2–1
737
9716
2
Nol Batist
France
2–1
1–1
674
9433
3
Bjorn Van Ryckeghem
France
2–2
3–1
674
9264
4
Christian Anton Smedshaug
England
1–2
1–2
659
9134
5
Perry Springintveld
Spain
1–1
2–1
647
9105
6
Willem Tijssen
Spain
2–0
2–1
710
9098
7
Hans Borsboom
Spain
2–1
2–1
528
9058
8
Bart Triemstra
Spain
2–1
2–1
737
9052
9
Youness Bensaid
Spain
2–1
1–1
722
8954
10
Vijay Dijkstra
Portugal
2–0
2–1
382
8953
However, there have been some surprises during the tournament, and bonus points must be added, so we will keep the suspense a little longer. On Monday we will find out who is the main World Cup announcer in the international fruit, vegetable and horticulture sector…